Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings per share estimates for shares of Immix Biopharma in a research report issued to clients and investors on Monday, January 6th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.87) per share for the year, down from their prior forecast of ($0.67). HC Wainwright currently has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Immix Biopharma's current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Immix Biopharma's Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.85) EPS.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08).
Immix Biopharma Price Performance
IMMX traded down $0.03 on Thursday, reaching $2.25. 74,229 shares of the company traded hands, compared to its average volume of 74,606. Immix Biopharma has a 52-week low of $1.26 and a 52-week high of $6.67. The company has a market cap of $61.89 million, a price-to-earnings ratio of -2.65 and a beta of 0.27. The stock's 50 day moving average price is $2.02 and its 200-day moving average price is $1.95.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Immix Biopharma stock. Invst LLC acquired a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 27,000 shares of the company's stock, valued at approximately $57,000. Invst LLC owned 0.10% of Immix Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.26% of the company's stock.
Immix Biopharma Company Profile
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
